Search

Your search keyword '"Singh, Mallika"' showing total 340 results
Start Over Author "Singh, Mallika"
340 results on '"Singh, Mallika"'

1. Advancing clinical trial outcomes using deep learning and predictive modelling: bridging precision medicine and patient-centered care

Author

Anuyah, Sydney, Singh, Mallika K, and Nyavor, Hope

Subjects
Computer Science - Machine Learning
Abstract

The integration of artificial intelligence [AI] into clinical trials has revolutionized the process of drug development and personalized medicine. Among these advancements, deep learning and predictive modelling have emerged as transformative tools for optimizing clinical trial design, patient recruitment, and real-time monitoring. This study explores the application of deep learning techniques, such as convolutional neural networks [CNNs] and transformerbased models, to stratify patients, forecast adverse events, and personalize treatment plans. Furthermore, predictive modelling approaches, including survival analysis and time-series forecasting, are employed to predict trial outcomes, enhancing efficiency and reducing trial failure rates. To address challenges in analysing unstructured clinical data, such as patient notes and trial protocols, natural language processing [NLP] techniques are utilized for extracting actionable insights. A custom dataset comprising structured patient demographics, genomic data, and unstructured text is curated for training and validating these models. Key metrics, including precision, recall, and F1 scores, are used to evaluate model performance, while trade-offs between accuracy and computational efficiency are examined to identify the optimal model for clinical deployment. This research underscores the potential of AI-driven methods to streamline clinical trial workflows, improve patient-centric outcomes, and reduce costs associated with trial inefficiencies. The findings provide a robust framework for integrating predictive analytics into precision medicine, paving the way for more adaptive and efficient clinical trials. By bridging the gap between technological innovation and real-world applications, this study contributes to advancing the role of AI in healthcare, particularly in fostering personalized care and improving overall trial success rates., Comment: 22 pages excluding references, 11 figures, 6 tables

Published
2024
Full Text
View/download PDF

4. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Author

Wasko, Urszula N., Jiang, Jingjing, Dalton, Tanner C., Curiel-Garcia, Alvaro, Edwards, A. Cole, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Tian, Sha, Stalnecker, Clint A., Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Stephen A., Palermo, Carmine F., Hasselluhn, Marie C., Decker-Farrell, Amanda R., Chang, Stephanie, Jiang, Lingyan, Wei, Xing, Yang, Yu C., Helland, Ciara, Courtney, Haley, Gindin, Yevgeniy, Muonio, Karl, Zhao, Ruiping, Kemp, Samantha B., Clendenin, Cynthia, Sor, Rina, Vostrejs, William P., Hibshman, Priya S., Amparo, Amber M., Hennessey, Connor, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Brodbeck, Jens, Tomassoni, Lorenzo, Bakir, Basil, Socci, Nicholas D., Herring, Laura E., Barker, Natalie K., Wang, Junning, Cleary, James M., Wolpin, Brian M., Chabot, John A., Kluger, Michael D., Manji, Gulam A., Tsai, Kenneth Y., Sekulic, Miroslav, Lagana, Stephen M., Califano, Andrea, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A. M., Holderfield, Matthew, Wildes, David, Lowe, Scott W., Badgley, Michael A., Aguirre, Andrew J., Vonderheide, Robert H., Stanger, Ben Z., Baslan, Timour, Der, Channing J., Singh, Mallika, and Olive, Kenneth P.

Published
2024
Full Text
View/download PDF

5. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Author

Holderfield, Matthew, Lee, Bianca J., Jiang, Jingjing, Tomlinson, Aidan, Seamon, Kyle J., Mira, Alessia, Patrucco, Enrico, Goodhart, Grace, Dilly, Julien, Gindin, Yevgeniy, Dinglasan, Nuntana, Wang, Yingyun, Lai, Lick Pui, Cai, Shurui, Jiang, Lingyan, Nasholm, Nicole, Shifrin, Nataliya, Blaj, Cristina, Shah, Harshit, Evans, James W., Montazer, Nilufar, Lai, Oliver, Shi, Jade, Ahler, Ethan, Quintana, Elsa, Chang, Stephanie, Salvador, Anthony, Marquez, Abby, Cregg, Jim, Liu, Yang, Milin, Anthony, Chen, Anqi, Ziv, Tamar Bar, Parsons, Dylan, Knox, John E., Klomp, Jennifer E., Roth, Jennifer, Rees, Matthew, Ronan, Melissa, Cuevas-Navarro, Antonio, Hu, Feng, Lito, Piro, Santamaria, David, Aguirre, Andrew J., Waters, Andrew M., Der, Channing J., Ambrogio, Chiara, Wang, Zhengping, Gill, Adrian L., Koltun, Elena S., Smith, Jacqueline A. M., Wildes, David, and Singh, Mallika

Published
2024
Full Text
View/download PDF

6. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

Author

Wasko, Urszula N., Jiang, Jingjing, Dalton, Tanner C., Curiel-Garcia, Alvaro, Edwards, A. Cole, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Tian, Sha, Stalnecker, Clint A., Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Stephen A., Palermo, Carmine F., Hasselluhn, Marie C., Decker-Farrell, Amanda R., Chang, Stephanie, Jiang, Lingyan, Wei, Xing, Yang, Yu C., Helland, Ciara, Courtney, Haley, Gindin, Yevgeniy, Muonio, Karl, Zhao, Ruiping, Kemp, Samantha B., Clendenin, Cynthia, Sor, Rina, Vostrejs, William P., Hibshman, Priya S., Amparo, Amber M., Hennessey, Connor, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Brodbeck, Jens, Tomassoni, Lorenzo, Bakir, Basil, Socci, Nicholas D., Herring, Laura E., Barker, Natalie K., Wang, Junning, Cleary, James M., Wolpin, Brian M., Chabot, John A., Kluger, Michael D., Manji, Gulam A., Tsai, Kenneth Y., Sekulic, Miroslav, Lagana, Stephen M., Califano, Andrea, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A. M., Holderfield, Matthew, Wildes, David, Lowe, Scott W., Badgley, Michael A., Aguirre, Andrew J., Vonderheide, Robert H., Stanger, Ben Z., Baslan, Timour, Der, Channing J., Singh, Mallika, and Olive, Kenneth P.

Published
2024
Full Text
View/download PDF

9. Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia

Author

Lee, Bianca J, Mallya, Sharmila, Dinglasan, Nuntana, Fung, Amos, Nguyen, Tram, Herzog, Lee-or, Thao, Joshua, Lorenzana, Edward G, Wildes, David, Singh, Mallika, Smith, Jacqueline AM, and Fruman, David A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Childhood Leukemia, Orphan Drug, Cancer, Pediatric Cancer, Rare Diseases, Pediatric, Hematology, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, mTORC1, targeted (selective) treatment, 4EBP1, combination therapy, Ph plus B-ALL, Ph+ B-ALL, Clinical sciences, Oncology and carcinogenesis
Abstract

The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) are mTORC1 substrates with an integral role in oncogenic protein translation. Current pharmacological approaches to inhibit mTORC1 activity and 4E-BP phosphorylation have drawbacks. Recently we described a series of bi-steric compounds that are potent and selective inhibitors of mTORC1, inhibiting 4E-BP phosphorylation at lower concentrations than mTOR kinase inhibitors (TOR-KIs). Here we report the activity of the mTORC1-selective bi-steric inhibitor, RMC-4627, in BCR-ABL-driven models of B-cell acute lymphoblastic leukemia (B-ALL). RMC-4627 exhibited potent and selective inhibition of 4E-BP1 phosphorylation in B-ALL cell lines without inhibiting mTOR-complex-2 (mTORC2) activity. RMC-4627 suppressed cell cycle progression, reduced survival, and enhanced dasatinib cytotoxicity. Compared to a TOR-KI compound, RMC-4627 was more potent, and its effects on cell viability were sustained after washout in vitro. Notably, a once-weekly, well tolerated dose reduced leukemic burden in a B-ALL xenograft model and enhanced the activity of dasatinib. These preclinical studies suggest that intermittent dosing of a bi-steric mTORC1-selective inhibitor has therapeutic potential as a component of leukemia regimens, and further study is warranted.

Published
2021

10. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity

Author

Myers, Darienne R, Abram, Clare L, Wildes, David, Belwafa, Amira, Welsh, Alia MN, Schulze, Christopher J, Choy, Tiffany J, Nguyen, Tram, Omaque, Neil, Hu, Yongmei, Singh, Mallika, Hansen, Rich, Goldsmith, Mark A, Quintana, Elsa, Smith, Jacqueline AM, and Lowell, Clifford A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Vaccine Related, Immunotherapy, Immunization, 2.1 Biological and endogenous factors, 5.1 Pharmaceuticals, Adaptive Immunity, Adenocarcinoma, Animals, Antigens, Differentiation, Breast Neoplasms, Colonic Neoplasms, Female, Humans, Immunity, Innate, Lymphocytes, Tumor-Infiltrating, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Knockout, Phagocytosis, Protein Tyrosine Phosphatase, Non-Receptor Type 6, Receptors, Immunologic, Signal Transduction, Skin Neoplasms, THP-1 Cells, Tumor Burden, Tumor Microenvironment, Tumor-Associated Macrophages, tyrosine phosphatase, phagocytosis, PTPN6, immuno-oncology, SIRP alpha, inflammation, SIRPα, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

Shp1, encoded by the gene Ptpn6, is a protein tyrosine phosphatase that transduces inhibitory signals downstream of immunoreceptors in many immune cell types. Blocking Shp1 activity represents an exciting potential immunotherapeutic strategy for the treatment of cancer, as Shp1 inhibition would be predicted to unleash both innate and adaptive immunity against tumor cells. Antibodies blocking the interaction between CD47 on tumor cells and SIRPα on macrophages enhance macrophage phagocytosis, show efficacy in preclinical tumor models, and are being evaluated in the clinic. Here we found that Shp1 bound to phosphorylated peptide sequences derived from SIRPα and transduced the anti-phagocytic signal, as Shp1 loss in mouse bone marrow-derived macrophages increased phagocytosis of tumor cells in vitro. We also generated a novel mouse model to evaluate the impact of global, inducible Ptpn6 deletion on anti-tumor immunity. We found that inducible Shp1 loss drove an inflammatory disease in mice that was phenotypically similar to that seen when Ptpn6 is knocked out from birth. This indicates that acute perturbation of Shp1 in vivo could drive hyperactivation of immune cells, which could be therapeutically beneficial, though at the risk of potential toxicity. In this model, we found that Shp1 loss led to robust anti-tumor immunity against two immune-rich syngeneic tumor models that are moderately inflamed though not responsive to checkpoint inhibitors, MC38 and E0771. Shp1 loss did not promote anti-tumor activity in the non-inflamed B16F10 model. The observed activity in MC38 and E0771 tumors was likely due to effects of both innate and adaptive immune cells. Following Shp1 deletion, we observed increases in intratumoral myeloid cells in both models, which was more striking in E0771 tumors. E0771 tumors also contained an increased ratio of effector to regulatory T cells following Shp1 loss. This was not observed for MC38 tumors, though we did find increased levels of IFNγ, a cytokine produced by effector T cells, in these tumors. Overall, our preclinical data suggested that targeting Shp1 may be an attractive therapeutic strategy for boosting the immune response to cancer via a mechanism involving both innate and adaptive leukocytes.

Published
2020

11. Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1

Author

Du, Heng, Yang, Yu Chi, Liu, Heng-Jia, Yuan, Min, Asara, John M., Wong, Kwok- Kin, Henske, Elizabeth P., Singh, Mallika, and Kwiatkowski, David J.

Subjects
Drug therapy, Physiological aspects, Usage, Development and progression, Health aspects, Apoptosis -- Health aspects, Protein kinases -- Physiological aspects -- Health aspects, Kinase inhibitors -- Physiological aspects -- Usage -- Health aspects, Tumors -- Drug therapy -- Development and progression
Abstract

Introduction The PI3K/AKT/mTOR network is a critical intracellular signaling pathway directing cell growth and metabolism in physiological and pathological conditions (1). The evolutionarily conserved mammalian target of rapamycin (mTOR) is [...], The PI3K/AKT/mTOR pathway is commonly dysregulated in cancer. Rapalogs exhibit modest clinical benefit, likely owing to their lack of effects on 4EBP1. We hypothesized that bi-steric mTORC1-selective inhibitors would have greater potential for clinical benefit than rapalogs in tumors with mTORC1 dysfunction. We assessed this hypothesis in tumor models with high mTORC1 activity both in vitro and in vivo. Bi-steric inhibitors had strong growth inhibition, eliminated phosphorylated 4EBP1, and induced more apoptosis than rapamycin or MLN0128. Multiomics analysis showed extensive effects of the bi-steric inhibitors in comparison with rapamycin. De novo purine synthesis was selectively inhibited by bi-sterics through reduction in JUN and its downstream target PRPS1 and appeared to be the cause of apoptosis. Hence, bi-steric mTORC1-selective inhibitors are a therapeutic strategy to treat tumors driven by mTORC1 hyperactivation.

Published
2023
Full Text
View/download PDF

12. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Author

Nichols, Robert J, Haderk, Franziska, Stahlhut, Carlos, Schulze, Christopher J, Hemmati, Golzar, Wildes, David, Tzitzilonis, Christos, Mordec, Kasia, Marquez, Abby, Romero, Jason, Hsieh, Tientien, Zaman, Aubhishek, Olivas, Victor, McCoach, Caroline, Blakely, Collin M, Wang, Zhengping, Kiss, Gert, Koltun, Elena S, Gill, Adrian L, Singh, Mallika, Goldsmith, Mark A, Smith, Jacqueline AM, and Bivona, Trever G

Subjects
Biochemistry and Cell Biology, Biological Sciences, Cancer, 5.1 Pharmaceuticals, Animals, Antineoplastic Agents, Biomarkers, Tumor, Cell Line, Tumor, Enzyme Inhibitors, Extracellular Signal-Regulated MAP Kinases, Genetic Predisposition to Disease, Guanosine Triphosphate, HEK293 Cells, Humans, Mice, Inbred BALB C, Mice, Nude, Mitogen-Activated Protein Kinase Kinases, Mutation, Neoplasms, Neurofibromin 1, Phenotype, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins p21(ras), SOS1 Protein, Signal Transduction, Tumor Burden, Xenograft Model Antitumor Assays, raf Kinases, Medical and Health Sciences, Developmental Biology, Biochemistry and cell biology
Abstract

Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS. Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-molecule allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRASG12C). SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading. Our findings illuminate a critical function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS. SHP2 inhibition is a promising molecular therapeutic strategy for patients with cancers bearing these oncogenic drivers.

Published
2018

14. Supplementary Table S8 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Author

Jiang, Jingjing, primary, Jiang, Lingyan, primary, Maldonato, Benjamin J., primary, Wang, Yingyun, primary, Holderfield, Matthew, primary, Aronchik, Ida, primary, Winters, Ian P., primary, Salman, Zeena, primary, Blaj, Cristina, primary, Menard, Marie, primary, Brodbeck, Jens, primary, Chen, Zhe, primary, Wei, Xing, primary, Rosen, Michael J., primary, Gindin, Yevgeniy, primary, Lee, Bianca J., primary, Evans, James W., primary, Chang, Stephanie, primary, Wang, Zhican, primary, Seamon, Kyle J., primary, Parsons, Dylan, primary, Cregg, James, primary, Marquez, Abby, primary, Tomlinson, Aidan C.A., primary, Yano, Jason K., primary, Knox, John E., primary, Quintana, Elsa, primary, Aguirre, Andrew J., primary, Arbour, Kathryn C., primary, Reed, Abby, primary, Gustafson, W. Clay, primary, Gill, Adrian L., primary, Koltun, Elena S., primary, Wildes, David, primary, Smith, Jacqueline A.M., primary, Wang, Zhengping, primary, and Singh, Mallika, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure S1-S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Author

Jiang, Jingjing, primary, Jiang, Lingyan, primary, Maldonato, Benjamin J., primary, Wang, Yingyun, primary, Holderfield, Matthew, primary, Aronchik, Ida, primary, Winters, Ian P., primary, Salman, Zeena, primary, Blaj, Cristina, primary, Menard, Marie, primary, Brodbeck, Jens, primary, Chen, Zhe, primary, Wei, Xing, primary, Rosen, Michael J., primary, Gindin, Yevgeniy, primary, Lee, Bianca J., primary, Evans, James W., primary, Chang, Stephanie, primary, Wang, Zhican, primary, Seamon, Kyle J., primary, Parsons, Dylan, primary, Cregg, James, primary, Marquez, Abby, primary, Tomlinson, Aidan C.A., primary, Yano, Jason K., primary, Knox, John E., primary, Quintana, Elsa, primary, Aguirre, Andrew J., primary, Arbour, Kathryn C., primary, Reed, Abby, primary, Gustafson, W. Clay, primary, Gill, Adrian L., primary, Koltun, Elena S., primary, Wildes, David, primary, Smith, Jacqueline A.M., primary, Wang, Zhengping, primary, and Singh, Mallika, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Method from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Author

Jiang, Jingjing, primary, Jiang, Lingyan, primary, Maldonato, Benjamin J., primary, Wang, Yingyun, primary, Holderfield, Matthew, primary, Aronchik, Ida, primary, Winters, Ian P., primary, Salman, Zeena, primary, Blaj, Cristina, primary, Menard, Marie, primary, Brodbeck, Jens, primary, Chen, Zhe, primary, Wei, Xing, primary, Rosen, Michael J., primary, Gindin, Yevgeniy, primary, Lee, Bianca J., primary, Evans, James W., primary, Chang, Stephanie, primary, Wang, Zhican, primary, Seamon, Kyle J., primary, Parsons, Dylan, primary, Cregg, James, primary, Marquez, Abby, primary, Tomlinson, Aidan C.A., primary, Yano, Jason K., primary, Knox, John E., primary, Quintana, Elsa, primary, Aguirre, Andrew J., primary, Arbour, Kathryn C., primary, Reed, Abby, primary, Gustafson, W. Clay, primary, Gill, Adrian L., primary, Koltun, Elena S., primary, Wildes, David, primary, Smith, Jacqueline A.M., primary, Wang, Zhengping, primary, and Singh, Mallika, primary

Published
2024
Full Text
View/download PDF

17. Data from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Author

Jiang, Jingjing, primary, Jiang, Lingyan, primary, Maldonato, Benjamin J., primary, Wang, Yingyun, primary, Holderfield, Matthew, primary, Aronchik, Ida, primary, Winters, Ian P., primary, Salman, Zeena, primary, Blaj, Cristina, primary, Menard, Marie, primary, Brodbeck, Jens, primary, Chen, Zhe, primary, Wei, Xing, primary, Rosen, Michael J., primary, Gindin, Yevgeniy, primary, Lee, Bianca J., primary, Evans, James W., primary, Chang, Stephanie, primary, Wang, Zhican, primary, Seamon, Kyle J., primary, Parsons, Dylan, primary, Cregg, James, primary, Marquez, Abby, primary, Tomlinson, Aidan C.A., primary, Yano, Jason K., primary, Knox, John E., primary, Quintana, Elsa, primary, Aguirre, Andrew J., primary, Arbour, Kathryn C., primary, Reed, Abby, primary, Gustafson, W. Clay, primary, Gill, Adrian L., primary, Koltun, Elena S., primary, Wildes, David, primary, Smith, Jacqueline A.M., primary, Wang, Zhengping, primary, and Singh, Mallika, primary

Published
2024
Full Text
View/download PDF

18. Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Author

Lee, Bianca J., Boyer, Jacob A., Burnett, G. Leslie, Thottumkara, Arun P., Tibrewal, Nidhi, Wilson, Stacy L., Hsieh, Tientien, Marquez, Abby, Lorenzana, Edward G., Evans, James W., Hulea, Laura, Kiss, Gert, Liu, Hui, Lee, Dong, Larsson, Ola, McLaughlan, Shannon, Topisirovic, Ivan, Wang, Zhengping, Wang, Zhican, Zhao, Yongyuan, Wildes, David, Aggen, James B., Singh, Mallika, Gill, Adrian L., Smith, Jacqueline A. M., and Rosen, Neal

Published
2021
Full Text
View/download PDF

19. Computed tomography‐based automated 3D measurement of femoral version: Validation against standard 2D measurements in symptomatic patients.

Author

Schmaranzer, Florian, Movahhedi, Mohammadreza, Singh, Mallika, Kallini, Jennifer R., Nanavati, Andreas K., Steppacher, Simon D., Heimann, Alexander F., Kiapour, Ata M., and Novais, Eduardo N.

Subjects
INTRACLASS correlation, DEEP learning, UNITS of measurement, FEMUR, CONFIDENCE intervals
Abstract

To validate 3D methods for femoral version measurement, we asked: (1) Can a fully automated segmentation of the entire femur and 3D measurement of femoral version using a neck based method and a head‐shaft based method be performed? (2) How do automatic 3D‐based computed tomography (CT) measurements of femoral version compare to the most commonly used 2D‐based measurements utilizing four different landmarks? Retrospective study (May 2017 to June 2018) evaluating 45 symptomatic patients (57 hips, mean age 18.7 ± 5.1 years) undergoing pelvic and femoral CT. Femoral version was assessed using four previously described methods (Lee, Reikeras, Tomczak, and Murphy). Fully‐automated segmentation yielded 3D femur models used to measure femoral version via femoral neck‐ and head‐shaft approaches. Mean femoral version with 95% confidence intervals, and intraclass correlation coefficients were calculated, and Bland‐Altman analysis was performed. Automatic 3D segmentation was highly accurate, with mean dice coefficients of 0.98 ± 0.03 and 0.97 ± 0.02 for femur/pelvis, respectively. Mean difference between 3D head‐shaft‐ (27.4 ± 16.6°) and 3D neck methods (12.9 ± 13.7°) was 14.5 ± 10.7° (p < 0.001). The 3D neck method was closer to the proximal Lee (−2.4 ± 5.9°, −4.4 to 0.5°, p = 0.009) and Reikeras (2 ± 5.6°, 95% CI: 0.2 to 3.8°, p = 0.03) methods. The 3D head‐shaft method was closer to the distal Tomczak (−1.3 ± 7.5°, 95% CI: −3.8 to 1.1°, p = 0.57) and Murphy (1.5 ± 5.4°, −0.3 to 3.3°, p = 0.12) methods. Automatic 3D neck‐based‐/head‐shaft methods yielded femoral version angles comparable to the proximal/distal 2D‐based methods, when applying fully‐automated segmentations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Comprehensive evaluation of magnetic resonance imaging sequences for signal intensity based assessment of anterior cruciate ligament healing following surgical treatment

Author

Kaushal, Shankar G., primary, Kim, Jin‐Young, additional, Singh, Mallika, additional, Han, Mo, additional, Flannery, Sean W., additional, Barnes, Dominique A., additional, Ecklund, Kirsten, additional, Murray, Martha M., additional, Badger, Gary J., additional, Fleming, Braden C., additional, and Kiapour, Ata M., additional

Published
2024
Full Text
View/download PDF

22. Abstract B080: Mutant-selective KRASG12D(ON) inhibitor suppresses proliferation in vitro and tumor growth in vivo of KrasG12D GEMM-derived PDAC organoids

Author

Labrecque, Mark P., primary, Jiang, Lingyan, additional, Nasholm, Nicole, additional, Nayak, Biswadeep, additional, Yu, Xinxing, additional, Song, Avian, additional, Weller, Caroline, additional, Evans, James W., additional, Zafra, Maria Paz, additional, Parsons, Marie, additional, Menard, Marie, additional, Dow, Lukas E., additional, Jiang, Jingjing, additional, Aronchik, Ida, additional, and Singh, Mallika, additional

Published
2024
Full Text
View/download PDF

23. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma

Author

Wasko, Urszula N., primary, Jiang, Jingjing, additional, Curiel-Garcia, Alvaro, additional, Wang, Yingyun, additional, Lee, Bianca, additional, Orlen, Margo, additional, Drizyte-Miller, Kristina, additional, Menard, Marie, additional, Dilly, Julien, additional, Sastra, Stephen A., additional, Palermo, Carmine F., additional, Dalton, Tanner, additional, Hasselluhn, Marie C., additional, Decker-Farrell, Amanda R., additional, Chang, Stephanie, additional, Jiang, Lingyan, additional, Wei, Xing, additional, Yang, Yu C., additional, Helland, Ciara, additional, Courtney, Haley, additional, Gindin, Yevgeniy, additional, Zhao, Ruiping, additional, Kemp, Samantha B., additional, Clendenin, Cynthia, additional, Sor, Rina, additional, Vostrejs, Will, additional, Amparo, Amber A., additional, Hibshman, Priya S., additional, Rees, Matthew G., additional, Ronan, Melissa M., additional, Roth, Jennifer A., additional, Bakir, Basil, additional, Badgley, Michael A., additional, Chabot, John A., additional, Kluger, Michael D., additional, Manji, Gulam A., additional, Quintana, Elsa, additional, Wang, Zhengping, additional, Smith, Jacqueline A. M., additional, Holderfield, Matthew, additional, Wildes, David, additional, Aguirre, Andrew J., additional, Der, Channing J., additional, Vonderheide, Robert H., additional, Stanger, Ben Z., additional, Singh, Mallika, additional, and Olive, Kenneth P., additional

Published
2023
Full Text
View/download PDF

25. Systematic evaluation of common natural language processing techniques to codify clinical notes.

Author

Tavabi, Nazgol, Singh, Mallika, Pruneski, James, and Kiapour, Ata M.

Subjects
*LANGUAGE models, *NATURAL language processing, *HUMAN error
Abstract

Proper codification of medical diagnoses and procedures is essential for optimized health care management, quality improvement, research, and reimbursement tasks within large healthcare systems. Assignment of diagnostic or procedure codes is a tedious manual process, often prone to human error. Natural Language Processing (NLP) has been suggested to facilitate this manual codification process. Yet, little is known on best practices to utilize NLP for such applications. With Large Language Models (LLMs) becoming more ubiquitous in daily life, it is critical to remember, not every task requires that level of resource and effort. Here we comprehensively assessed the performance of common NLP techniques to predict current procedural terminology (CPT) from operative notes. CPT codes are commonly used to track surgical procedures and interventions and are the primary means for reimbursement. Our analysis of 100 most common musculoskeletal CPT codes suggest that traditional approaches can outperform more resource intensive approaches like BERT significantly (P-value = 4.4e-17) with average AUROC of 0.96 and accuracy of 0.97, in addition to providing interpretability which can be very helpful and even crucial in the clinical domain. We also proposed a complexity measure to quantify the complexity of a classification task and how this measure could influence the effect of dataset size on model's performance. Finally, we provide preliminary evidence that NLP can help minimize the codification error, including mislabeling due to human error. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Author

Schulze, Christopher J., primary, Seamon, Kyle J., additional, Zhao, Yulei, additional, Yang, Yu C., additional, Cregg, Jim, additional, Kim, Dongsung, additional, Tomlinson, Aidan, additional, Choy, Tiffany J., additional, Wang, Zhican, additional, Sang, Ben, additional, Pourfarjam, Yasin, additional, Lucas, Jessica, additional, Cuevas-Navarro, Antonio, additional, Ayala-Santos, Carlos, additional, Vides, Alberto, additional, Li, Chuanchuan, additional, Marquez, Abby, additional, Zhong, Mengqi, additional, Vemulapalli, Vidyasiri, additional, Weller, Caroline, additional, Gould, Andrea, additional, Whalen, Daniel M., additional, Salvador, Anthony, additional, Milin, Anthony, additional, Saldajeno-Concar, Mae, additional, Dinglasan, Nuntana, additional, Chen, Anqi, additional, Evans, Jim, additional, Knox, John E., additional, Koltun, Elena S., additional, Singh, Mallika, additional, Nichols, Robert, additional, Wildes, David, additional, Gill, Adrian L., additional, Smith, Jacqueline A. M., additional, and Lito, Piro, additional

Published
2023
Full Text
View/download PDF

28. Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Author

Lee, Bianca J., Boyer, Jacob A., Burnett, G. Leslie, Thottumkara, Arun P., Tibrewal, Nidhi, Wilson, Stacy L., Hsieh, Tientien, Marquez, Abby, Lorenzana, Edward G., Evans, James W., Hulea, Laura, Kiss, Gert, Liu, Hui, Lee, Dong, Larsson, Ola, McLaughlan, Shannon, Topisirovic, Ivan, Wang, Zhengping, Wang, Zhican, Zhao, Yongyuan, Wildes, David, Aggen, James B., Singh, Mallika, Gill, Adrian L., Smith, Jacqueline A. M., and Rosen, Neal

Published
2021
Full Text
View/download PDF

30. Abstract LB015: Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression

Author

Mahauad-Fernandez, Wadie D., primary, Yang, Yu Chi, additional, Lai, Ian, additional, Park, Jangho, additional, Yao, Lilian, additional, Evans, James W., additional, Atibalentja, Danielle F., additional, Chen, Xinyu, additional, Zhao, Zihui, additional, Burnett, G. Leslie, additional, Lee, Bianca J., additional, Dinglasan, Nuntana, additional, Shifrin, Nataliya, additional, Ahler, Ethan, additional, Quintana, Elsa, additional, Gill, Adrian, additional, Smith, Jacqueline A., additional, Singh, Mallika, additional, and Felsher, Dean W., additional

Published
2023
Full Text
View/download PDF

31. Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

Author

Jiang, Lingyan, primary, Menard, Marie, additional, Weller, Caroline, additional, Wang, Zhican, additional, Burnett, Les, additional, Aronchik, Ida, additional, Steele, Shelby, additional, Flagella, Mike, additional, Zhao, Ruiping, additional, Evans, James W W., additional, Chin, Shook, additional, Chou, Kang-Jye, additional, Mu, Yunming, additional, Longhi, Michael, additional, McDowell, Laura, additional, Knox, John E., additional, Gill, Adrian, additional, Smith, Jacqueline A., additional, Singh, Mallika, additional, Quintana, Elsa, additional, and Jiang, Jingjing, additional

Published
2023
Full Text
View/download PDF

32. Abstract 1598: RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Author

Yang, Yu C., primary, Thompson, Severin, additional, Montgomery, David, additional, Quiñones, Antonio J., additional, Wei, Xing, additional, Madej, Benjamin, additional, Tomlinson, Aidan, additional, Shifrin, Nataliya T., additional, McNamara, Alexander, additional, Ahler, Ethan, additional, McDowell, Laura L., additional, Flagella, Michael, additional, Setser, John, additional, Chang, Stephanie, additional, Wang, Zhican, additional, Wang, Zhengping, additional, Huang, Jun, additional, Ballmer, Steve, additional, li, Shaong, additional, Buckl, Andreas, additional, Koltun, Elena, additional, Gill, Adrian, additional, Jiang, Jingjing, additional, Singh, Mallika, additional, and Smith, Jacqueline A., additional

Published
2023
Full Text
View/download PDF

35. Supplemental Fig 1,2,3 from Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Author

Junttila, Melissa R., primary, Devasthali, Vidusha, primary, Cheng, Jason H., primary, Castillo, Joseph, primary, Metcalfe, Ciara, primary, Clermont, Anne C., primary, Otter, Douglas Den, primary, Chan, Emily, primary, Bou-Reslan, Hani, primary, Cao, Tim, primary, Forrest, William, primary, Nannini, Michelle A., primary, French, Dorothy, primary, Carano, Richard, primary, Merchant, Mark, primary, Hoeflich, Klaus P., primary, and Singh, Mallika, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

37. Supplemental legends from Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Author

Shao, Wenlin, primary, Mishina, Yuji M., primary, Feng, Yun, primary, Caponigro, Giordano, primary, Cooke, Vesselina G., primary, Rivera, Stacy, primary, Wang, Yingyun, primary, Shen, Fang, primary, Korn, Joshua M., primary, Mathews Griner, Lesley A., primary, Nishiguchi, Gisele, primary, Rico, Alice, primary, Tellew, John, primary, Haling, Jacob R., primary, Aversa, Robert, primary, Polyakov, Valery, primary, Zang, Richard, primary, Hekmat-Nejad, Mohammad, primary, Amiri, Payman, primary, Singh, Mallika, primary, Keen, Nicholas, primary, Dillon, Michael P., primary, Lees, Emma, primary, Ramurthy, Savithri, primary, Sellers, William R., primary, and Stuart, Darrin D., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods, Tables 1 - 3 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

40. Table S5 from Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Author

Shao, Wenlin, primary, Mishina, Yuji M., primary, Feng, Yun, primary, Caponigro, Giordano, primary, Cooke, Vesselina G., primary, Rivera, Stacy, primary, Wang, Yingyun, primary, Shen, Fang, primary, Korn, Joshua M., primary, Mathews Griner, Lesley A., primary, Nishiguchi, Gisele, primary, Rico, Alice, primary, Tellew, John, primary, Haling, Jacob R., primary, Aversa, Robert, primary, Polyakov, Valery, primary, Zang, Richard, primary, Hekmat-Nejad, Mohammad, primary, Amiri, Payman, primary, Singh, Mallika, primary, Keen, Nicholas, primary, Dillon, Michael P., primary, Lees, Emma, primary, Ramurthy, Savithri, primary, Sellers, William R., primary, and Stuart, Darrin D., primary

Published
2023
Full Text
View/download PDF

41. Tables S1, S4 from Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Author

Shao, Wenlin, primary, Mishina, Yuji M., primary, Feng, Yun, primary, Caponigro, Giordano, primary, Cooke, Vesselina G., primary, Rivera, Stacy, primary, Wang, Yingyun, primary, Shen, Fang, primary, Korn, Joshua M., primary, Mathews Griner, Lesley A., primary, Nishiguchi, Gisele, primary, Rico, Alice, primary, Tellew, John, primary, Haling, Jacob R., primary, Aversa, Robert, primary, Polyakov, Valery, primary, Zang, Richard, primary, Hekmat-Nejad, Mohammad, primary, Amiri, Payman, primary, Singh, Mallika, primary, Keen, Nicholas, primary, Dillon, Michael P., primary, Lees, Emma, primary, Ramurthy, Savithri, primary, Sellers, William R., primary, and Stuart, Darrin D., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 2 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

44. Figures S1, S2, S3, S4 from Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Author

Shao, Wenlin, primary, Mishina, Yuji M., primary, Feng, Yun, primary, Caponigro, Giordano, primary, Cooke, Vesselina G., primary, Rivera, Stacy, primary, Wang, Yingyun, primary, Shen, Fang, primary, Korn, Joshua M., primary, Mathews Griner, Lesley A., primary, Nishiguchi, Gisele, primary, Rico, Alice, primary, Tellew, John, primary, Haling, Jacob R., primary, Aversa, Robert, primary, Polyakov, Valery, primary, Zang, Richard, primary, Hekmat-Nejad, Mohammad, primary, Amiri, Payman, primary, Singh, Mallika, primary, Keen, Nicholas, primary, Dillon, Michael P., primary, Lees, Emma, primary, Ramurthy, Savithri, primary, Sellers, William R., primary, and Stuart, Darrin D., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 6 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 5 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 4 from Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Author

Brauer, Matthew J., primary, Zhuang, Guanglei, primary, Schmidt, Maike, primary, Yao, Jenny, primary, Wu, Xiumin, primary, Kaminker, Joshua S., primary, Jurinka, Stefanie S., primary, Kolumam, Ganesh, primary, Chung, Alicia S., primary, Jubb, Adrian, primary, Modrusan, Zora, primary, Ozawa, Tomoko, primary, James, C. David, primary, Phillips, Heidi, primary, Haley, Benjamin, primary, Tam, Rachel N.W., primary, Clermont, Anne C., primary, Cheng, Jason H., primary, Yang, Sherry X., primary, Swain, Sandra M., primary, Chen, Daniel, primary, Scherer, Stefan J., primary, Koeppen, Hartmut, primary, Yeh, Ru-Fang, primary, Yue, Peng, primary, Stephan, Jean-Philippe, primary, Hegde, Priti, primary, Ferrara, Napoleone, primary, Singh, Mallika, primary, and Bais, Carlos, primary

Published
2023
Full Text
View/download PDF

48. Contributors

Author

Aguirre, Andrew J., Ambrogio, Chiara, Boumelha, Jesse, Casey, Patrick J., Chugh, Seema, Cotesta, Simona, Cregg, James, Der, Channing J., Dow, Lukas E., Downward, Julian, Edwards, Anne V., Giddens, John P., Gill, Adrian L., Hansen, Rasmus, Janes, Matthew R., Jean-Francois, Frantz Louis, Knox, John E., Koltun, Elena S., Kraut, Norbert, Lanman, Brian A., Li, Liansheng, Lindsay, Colin R., Liu, Yi, Marquez, Abby, Marx, Mathew A., McConnell, Darryl B., McCormick, Frank, Milin, Anthony N., Molina-Arcas, Miriam, Nadal, Ernest, Patny, Akshay, Peters, Ulf, Philips, Mark R., Pota, Kristof, Ren, Pingda, Santamaria, David, Shiraishi, Takuya, Shokat, Kevan M., Simanshu, Dhirendra K., Simon, Daniel, Singh, Mallika, Tamayo, Nuria A., Tanada, Mikimasa, Tapioles, Cristina Nuevo, Tomlinson, Aidan, Wang, Mei, Wang, Xiaolun, Wurz, Ryan P., Zécri, Frédéric J., and Zhang, Ziyang

Published
2025
Full Text
View/download PDF

50. Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Author

Burnett, G. Leslie, primary, Yang, Yu C., additional, Aggen, James B., additional, Pitzen, Jennifer, additional, Gliedt, Micah K., additional, Semko, Chris M., additional, Marquez, Abby, additional, Evans, James W., additional, Wang, Gang, additional, Won, Walter S., additional, Tomlinson, Aidan C. A., additional, Kiss, Gert, additional, Tzitzilonis, Christos, additional, Thottumkara, Arun P., additional, Cregg, James, additional, Mellem, Kevin T., additional, Choi, Jong S., additional, Lee, Julie C., additional, Zhao, Yongyuan, additional, Lee, Bianca J., additional, Meyerowitz, Justin G., additional, Knox, John E., additional, Jiang, Jingjing, additional, Wang, Zhican, additional, Wildes, David, additional, Wang, Zhengping, additional, Singh, Mallika, additional, Smith, Jacqueline A. M., additional, and Gill, Adrian L., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results